![](https://endpts.com/wp-content/uploads/2023/10/Markus-Warmuth-Monte-Rosa-feature.jpg)
Markus Warmuth, Monte Rosa Therapeutics CEO
With a fresh $100M, Monte Rosa CEO details plans to move several molecular glues into the clinic
Monte Rosa Therapeutics CEO Markus Warmuth expects molecular glues to make up a new class of drugs with “almost unlimited potential” in the long run …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.